English
简体中文
Total: £ 56.28
Published Date: 2025-04-01 | Pages: 101 | Tables: 109 | Medical Care
The global market for CAR-NK Cell Therapy was valued at US$ 2361 million in the year 2024 and is projected to reach a revised size of US$ 3304 million by 2031, growing at a CAGR of 5.7% during the forecast period.
CAR-NK cell therapy is an advanced cellular therapy technique that combines the natural anticancer ability of natural killer (NK) cells with the specific targeting function of chimeric antigen receptors (CARs). Through genetic engineering, CAR structures capable of recognizing specific tumor antigens are introduced into NK cells, thereby enhancing their targeting ability and killing power. This therapy has shown great potential in treating various types of cancers, including hematological tumors and solid tumors. CAR-NK cell therapy has lower toxic and side effects and better safety, making it a promising supplement or alternative to CAR-T cell therapy.
North American market for CAR-NK Cell Therapy is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CAR-NK Cell Therapy is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CAR-NK Cell Therapy in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CAR-NK Cell Therapy include Artiva Biotherapeutics, Cartherics, Cytoimmune Therapeutics, Dragonfly Therapeutics, Fate Therapeutics, Glycostem Therapeutics, ImmuneBridge, ImmunityBio, Nkarta, NKGen Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CAR-NK Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-NK Cell Therapy.
The CAR-NK Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CAR-NK Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-NK Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Artiva Biotherapeutics
Cartherics
Cytoimmune Therapeutics
Dragonfly Therapeutics
Fate Therapeutics
Glycostem Therapeutics
ImmuneBridge
ImmunityBio
Nkarta
NKGen Biotech
ONK Therapeutics
Senti Biosciences
Base Therapeutics
Persongen
Alpha Biopharma
Guangzhou Doublle Bioproduct
Rui Therapeutics
Allife Medicine
Morecell
Simnova
Nuwacell
Segment by Type
Cytokine Therapy
Adoptive NK Cell Therapy
Genetically Engineered NK Cell Therapy
Others
Segment by Application
Solid Tumors
Hematological Malignancies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-NK Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-NK Cell Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cytokine Therapy
1.2.3 Adoptive NK Cell Therapy
1.2.4 Genetically Engineered NK Cell Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global CAR-NK Cell Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumors
1.3.3 Hematological Malignancies
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-NK Cell Therapy Market Perspective (2020-2031)
2.2 Global CAR-NK Cell Therapy Growth Trends by Region
2.2.1 Global CAR-NK Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CAR-NK Cell Therapy Historic Market Size by Region (2020-2025)
2.2.3 CAR-NK Cell Therapy Forecasted Market Size by Region (2026-2031)
2.3 CAR-NK Cell Therapy Market Dynamics
2.3.1 CAR-NK Cell Therapy Industry Trends
2.3.2 CAR-NK Cell Therapy Market Drivers
2.3.3 CAR-NK Cell Therapy Market Challenges
2.3.4 CAR-NK Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-NK Cell Therapy Players by Revenue
3.1.1 Global Top CAR-NK Cell Therapy Players by Revenue (2020-2025)
3.1.2 Global CAR-NK Cell Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Top CAR-NK Cell Therapy Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CAR-NK Cell Therapy Revenue
3.4 Global CAR-NK Cell Therapy Market Concentration Ratio
3.4.1 Global CAR-NK Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-NK Cell Therapy Revenue in 2024
3.5 Global Key Players of CAR-NK Cell Therapy Head office and Area Served
3.6 Global Key Players of CAR-NK Cell Therapy, Product and Application
3.7 Global Key Players of CAR-NK Cell Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-NK Cell Therapy Breakdown Data by Type
4.1 Global CAR-NK Cell Therapy Historic Market Size by Type (2020-2025)
4.2 Global CAR-NK Cell Therapy Forecasted Market Size by Type (2026-2031)
5 CAR-NK Cell Therapy Breakdown Data by Application
5.1 Global CAR-NK Cell Therapy Historic Market Size by Application (2020-2025)
5.2 Global CAR-NK Cell Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CAR-NK Cell Therapy Market Size (2020-2031)
6.2 North America CAR-NK Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CAR-NK Cell Therapy Market Size by Country (2020-2025)
6.4 North America CAR-NK Cell Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-NK Cell Therapy Market Size (2020-2031)
7.2 Europe CAR-NK Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CAR-NK Cell Therapy Market Size by Country (2020-2025)
7.4 Europe CAR-NK Cell Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-NK Cell Therapy Market Size (2020-2031)
8.2 Asia-Pacific CAR-NK Cell Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CAR-NK Cell Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific CAR-NK Cell Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-NK Cell Therapy Market Size (2020-2031)
9.2 Latin America CAR-NK Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CAR-NK Cell Therapy Market Size by Country (2020-2025)
9.4 Latin America CAR-NK Cell Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-NK Cell Therapy Market Size (2020-2031)
10.2 Middle East & Africa CAR-NK Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CAR-NK Cell Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa CAR-NK Cell Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Artiva Biotherapeutics
11.1.1 Artiva Biotherapeutics Company Details
11.1.2 Artiva Biotherapeutics Business Overview
11.1.3 Artiva Biotherapeutics CAR-NK Cell Therapy Introduction
11.1.4 Artiva Biotherapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.1.5 Artiva Biotherapeutics Recent Development
11.2 Cartherics
11.2.1 Cartherics Company Details
11.2.2 Cartherics Business Overview
11.2.3 Cartherics CAR-NK Cell Therapy Introduction
11.2.4 Cartherics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.2.5 Cartherics Recent Development
11.3 Cytoimmune Therapeutics
11.3.1 Cytoimmune Therapeutics Company Details
11.3.2 Cytoimmune Therapeutics Business Overview
11.3.3 Cytoimmune Therapeutics CAR-NK Cell Therapy Introduction
11.3.4 Cytoimmune Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.3.5 Cytoimmune Therapeutics Recent Development
11.4 Dragonfly Therapeutics
11.4.1 Dragonfly Therapeutics Company Details
11.4.2 Dragonfly Therapeutics Business Overview
11.4.3 Dragonfly Therapeutics CAR-NK Cell Therapy Introduction
11.4.4 Dragonfly Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.4.5 Dragonfly Therapeutics Recent Development
11.5 Fate Therapeutics
11.5.1 Fate Therapeutics Company Details
11.5.2 Fate Therapeutics Business Overview
11.5.3 Fate Therapeutics CAR-NK Cell Therapy Introduction
11.5.4 Fate Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.5.5 Fate Therapeutics Recent Development
11.6 Glycostem Therapeutics
11.6.1 Glycostem Therapeutics Company Details
11.6.2 Glycostem Therapeutics Business Overview
11.6.3 Glycostem Therapeutics CAR-NK Cell Therapy Introduction
11.6.4 Glycostem Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.6.5 Glycostem Therapeutics Recent Development
11.7 ImmuneBridge
11.7.1 ImmuneBridge Company Details
11.7.2 ImmuneBridge Business Overview
11.7.3 ImmuneBridge CAR-NK Cell Therapy Introduction
11.7.4 ImmuneBridge Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.7.5 ImmuneBridge Recent Development
11.8 ImmunityBio
11.8.1 ImmunityBio Company Details
11.8.2 ImmunityBio Business Overview
11.8.3 ImmunityBio CAR-NK Cell Therapy Introduction
11.8.4 ImmunityBio Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.8.5 ImmunityBio Recent Development
11.9 Nkarta
11.9.1 Nkarta Company Details
11.9.2 Nkarta Business Overview
11.9.3 Nkarta CAR-NK Cell Therapy Introduction
11.9.4 Nkarta Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.9.5 Nkarta Recent Development
11.10 NKGen Biotech
11.10.1 NKGen Biotech Company Details
11.10.2 NKGen Biotech Business Overview
11.10.3 NKGen Biotech CAR-NK Cell Therapy Introduction
11.10.4 NKGen Biotech Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.10.5 NKGen Biotech Recent Development
11.11 ONK Therapeutics
11.11.1 ONK Therapeutics Company Details
11.11.2 ONK Therapeutics Business Overview
11.11.3 ONK Therapeutics CAR-NK Cell Therapy Introduction
11.11.4 ONK Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.11.5 ONK Therapeutics Recent Development
11.12 Senti Biosciences
11.12.1 Senti Biosciences Company Details
11.12.2 Senti Biosciences Business Overview
11.12.3 Senti Biosciences CAR-NK Cell Therapy Introduction
11.12.4 Senti Biosciences Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.12.5 Senti Biosciences Recent Development
11.13 Base Therapeutics
11.13.1 Base Therapeutics Company Details
11.13.2 Base Therapeutics Business Overview
11.13.3 Base Therapeutics CAR-NK Cell Therapy Introduction
11.13.4 Base Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.13.5 Base Therapeutics Recent Development
11.14 Persongen
11.14.1 Persongen Company Details
11.14.2 Persongen Business Overview
11.14.3 Persongen CAR-NK Cell Therapy Introduction
11.14.4 Persongen Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.14.5 Persongen Recent Development
11.15 Alpha Biopharma
11.15.1 Alpha Biopharma Company Details
11.15.2 Alpha Biopharma Business Overview
11.15.3 Alpha Biopharma CAR-NK Cell Therapy Introduction
11.15.4 Alpha Biopharma Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.15.5 Alpha Biopharma Recent Development
11.16 Guangzhou Doublle Bioproduct
11.16.1 Guangzhou Doublle Bioproduct Company Details
11.16.2 Guangzhou Doublle Bioproduct Business Overview
11.16.3 Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Introduction
11.16.4 Guangzhou Doublle Bioproduct Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.16.5 Guangzhou Doublle Bioproduct Recent Development
11.17 Rui Therapeutics
11.17.1 Rui Therapeutics Company Details
11.17.2 Rui Therapeutics Business Overview
11.17.3 Rui Therapeutics CAR-NK Cell Therapy Introduction
11.17.4 Rui Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.17.5 Rui Therapeutics Recent Development
11.18 Allife Medicine
11.18.1 Allife Medicine Company Details
11.18.2 Allife Medicine Business Overview
11.18.3 Allife Medicine CAR-NK Cell Therapy Introduction
11.18.4 Allife Medicine Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.18.5 Allife Medicine Recent Development
11.19 Morecell
11.19.1 Morecell Company Details
11.19.2 Morecell Business Overview
11.19.3 Morecell CAR-NK Cell Therapy Introduction
11.19.4 Morecell Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.19.5 Morecell Recent Development
11.20 Simnova
11.20.1 Simnova Company Details
11.20.2 Simnova Business Overview
11.20.3 Simnova CAR-NK Cell Therapy Introduction
11.20.4 Simnova Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.20.5 Simnova Recent Development
11.21 Nuwacell
11.21.1 Nuwacell Company Details
11.21.2 Nuwacell Business Overview
11.21.3 Nuwacell CAR-NK Cell Therapy Introduction
11.21.4 Nuwacell Revenue in CAR-NK Cell Therapy Business (2020-2025)
11.21.5 Nuwacell Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global CAR-NK Cell Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cytokine Therapy
Table 3. Key Players of Adoptive NK Cell Therapy
Table 4. Key Players of Genetically Engineered NK Cell Therapy
Table 5. Key Players of Others
Table 6. Global CAR-NK Cell Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global CAR-NK Cell Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global CAR-NK Cell Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global CAR-NK Cell Therapy Market Share by Region (2020-2025)
Table 10. Global CAR-NK Cell Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global CAR-NK Cell Therapy Market Share by Region (2026-2031)
Table 12. CAR-NK Cell Therapy Market Trends
Table 13. CAR-NK Cell Therapy Market Drivers
Table 14. CAR-NK Cell Therapy Market Challenges
Table 15. CAR-NK Cell Therapy Market Restraints
Table 16. Global CAR-NK Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global CAR-NK Cell Therapy Market Share by Players (2020-2025)
Table 18. Global Top CAR-NK Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-NK Cell Therapy as of 2024)
Table 19. Ranking of Global Top CAR-NK Cell Therapy Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by CAR-NK Cell Therapy Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of CAR-NK Cell Therapy, Headquarters and Area Served
Table 22. Global Key Players of CAR-NK Cell Therapy, Product and Application
Table 23. Global Key Players of CAR-NK Cell Therapy, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global CAR-NK Cell Therapy Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global CAR-NK Cell Therapy Revenue Market Share by Type (2020-2025)
Table 27. Global CAR-NK Cell Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global CAR-NK Cell Therapy Revenue Market Share by Type (2026-2031)
Table 29. Global CAR-NK Cell Therapy Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global CAR-NK Cell Therapy Revenue Market Share by Application (2020-2025)
Table 31. Global CAR-NK Cell Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global CAR-NK Cell Therapy Revenue Market Share by Application (2026-2031)
Table 33. North America CAR-NK Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America CAR-NK Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America CAR-NK Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe CAR-NK Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe CAR-NK Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe CAR-NK Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific CAR-NK Cell Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific CAR-NK Cell Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific CAR-NK Cell Therapy Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America CAR-NK Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America CAR-NK Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America CAR-NK Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa CAR-NK Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa CAR-NK Cell Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa CAR-NK Cell Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 48. Artiva Biotherapeutics Company Details
Table 49. Artiva Biotherapeutics Business Overview
Table 50. Artiva Biotherapeutics CAR-NK Cell Therapy Product
Table 51. Artiva Biotherapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 52. Artiva Biotherapeutics Recent Development
Table 53. Cartherics Company Details
Table 54. Cartherics Business Overview
Table 55. Cartherics CAR-NK Cell Therapy Product
Table 56. Cartherics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 57. Cartherics Recent Development
Table 58. Cytoimmune Therapeutics Company Details
Table 59. Cytoimmune Therapeutics Business Overview
Table 60. Cytoimmune Therapeutics CAR-NK Cell Therapy Product
Table 61. Cytoimmune Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 62. Cytoimmune Therapeutics Recent Development
Table 63. Dragonfly Therapeutics Company Details
Table 64. Dragonfly Therapeutics Business Overview
Table 65. Dragonfly Therapeutics CAR-NK Cell Therapy Product
Table 66. Dragonfly Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 67. Dragonfly Therapeutics Recent Development
Table 68. Fate Therapeutics Company Details
Table 69. Fate Therapeutics Business Overview
Table 70. Fate Therapeutics CAR-NK Cell Therapy Product
Table 71. Fate Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 72. Fate Therapeutics Recent Development
Table 73. Glycostem Therapeutics Company Details
Table 74. Glycostem Therapeutics Business Overview
Table 75. Glycostem Therapeutics CAR-NK Cell Therapy Product
Table 76. Glycostem Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 77. Glycostem Therapeutics Recent Development
Table 78. ImmuneBridge Company Details
Table 79. ImmuneBridge Business Overview
Table 80. ImmuneBridge CAR-NK Cell Therapy Product
Table 81. ImmuneBridge Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 82. ImmuneBridge Recent Development
Table 83. ImmunityBio Company Details
Table 84. ImmunityBio Business Overview
Table 85. ImmunityBio CAR-NK Cell Therapy Product
Table 86. ImmunityBio Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 87. ImmunityBio Recent Development
Table 88. Nkarta Company Details
Table 89. Nkarta Business Overview
Table 90. Nkarta CAR-NK Cell Therapy Product
Table 91. Nkarta Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 92. Nkarta Recent Development
Table 93. NKGen Biotech Company Details
Table 94. NKGen Biotech Business Overview
Table 95. NKGen Biotech CAR-NK Cell Therapy Product
Table 96. NKGen Biotech Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 97. NKGen Biotech Recent Development
Table 98. ONK Therapeutics Company Details
Table 99. ONK Therapeutics Business Overview
Table 100. ONK Therapeutics CAR-NK Cell Therapy Product
Table 101. ONK Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 102. ONK Therapeutics Recent Development
Table 103. Senti Biosciences Company Details
Table 104. Senti Biosciences Business Overview
Table 105. Senti Biosciences CAR-NK Cell Therapy Product
Table 106. Senti Biosciences Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 107. Senti Biosciences Recent Development
Table 108. Base Therapeutics Company Details
Table 109. Base Therapeutics Business Overview
Table 110. Base Therapeutics CAR-NK Cell Therapy Product
Table 111. Base Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 112. Base Therapeutics Recent Development
Table 113. Persongen Company Details
Table 114. Persongen Business Overview
Table 115. Persongen CAR-NK Cell Therapy Product
Table 116. Persongen Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 117. Persongen Recent Development
Table 118. Alpha Biopharma Company Details
Table 119. Alpha Biopharma Business Overview
Table 120. Alpha Biopharma CAR-NK Cell Therapy Product
Table 121. Alpha Biopharma Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 122. Alpha Biopharma Recent Development
Table 123. Guangzhou Doublle Bioproduct Company Details
Table 124. Guangzhou Doublle Bioproduct Business Overview
Table 125. Guangzhou Doublle Bioproduct CAR-NK Cell Therapy Product
Table 126. Guangzhou Doublle Bioproduct Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 127. Guangzhou Doublle Bioproduct Recent Development
Table 128. Rui Therapeutics Company Details
Table 129. Rui Therapeutics Business Overview
Table 130. Rui Therapeutics CAR-NK Cell Therapy Product
Table 131. Rui Therapeutics Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 132. Rui Therapeutics Recent Development
Table 133. Allife Medicine Company Details
Table 134. Allife Medicine Business Overview
Table 135. Allife Medicine CAR-NK Cell Therapy Product
Table 136. Allife Medicine Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 137. Allife Medicine Recent Development
Table 138. Morecell Company Details
Table 139. Morecell Business Overview
Table 140. Morecell CAR-NK Cell Therapy Product
Table 141. Morecell Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 142. Morecell Recent Development
Table 143. Simnova Company Details
Table 144. Simnova Business Overview
Table 145. Simnova CAR-NK Cell Therapy Product
Table 146. Simnova Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 147. Simnova Recent Development
Table 148. Nuwacell Company Details
Table 149. Nuwacell Business Overview
Table 150. Nuwacell CAR-NK Cell Therapy Product
Table 151. Nuwacell Revenue in CAR-NK Cell Therapy Business (2020-2025) & (US$ Million)
Table 152. Nuwacell Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. CAR-NK Cell Therapy Picture
Figure 2. Global CAR-NK Cell Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global CAR-NK Cell Therapy Market Share by Type: 2024 VS 2031
Figure 4. Cytokine Therapy Features
Figure 5. Adoptive NK Cell Therapy Features
Figure 6. Genetically Engineered NK Cell Therapy Features
Figure 7. Others Features
Figure 8. Global CAR-NK Cell Therapy Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global CAR-NK Cell Therapy Market Share by Application: 2024 VS 2031
Figure 10. Solid Tumors Case Studies
Figure 11. Hematological Malignancies Case Studies
Figure 12. Others Case Studies
Figure 13. CAR-NK Cell Therapy Report Years Considered
Figure 14. Global CAR-NK Cell Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global CAR-NK Cell Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global CAR-NK Cell Therapy Market Share by Region: 2024 VS 2031
Figure 17. Global CAR-NK Cell Therapy Market Share by Players in 2024
Figure 18. Global CAR-NK Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by CAR-NK Cell Therapy Revenue in 2024
Figure 20. North America CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America CAR-NK Cell Therapy Market Share by Country (2020-2031)
Figure 22. United States CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe CAR-NK Cell Therapy Market Share by Country (2020-2031)
Figure 26. Germany CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific CAR-NK Cell Therapy Market Share by Region (2020-2031)
Figure 34. China CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America CAR-NK Cell Therapy Market Share by Country (2020-2031)
Figure 42. Mexico CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa CAR-NK Cell Therapy Market Share by Country (2020-2031)
Figure 46. Turkey CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE CAR-NK Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Artiva Biotherapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 50. Cartherics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 51. Cytoimmune Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 52. Dragonfly Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 53. Fate Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 54. Glycostem Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 55. ImmuneBridge Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 56. ImmunityBio Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 57. Nkarta Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 58. NKGen Biotech Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 59. ONK Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 60. Senti Biosciences Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 61. Base Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 62. Persongen Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 63. Alpha Biopharma Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 64. Guangzhou Doublle Bioproduct Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 65. Rui Therapeutics Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 66. Allife Medicine Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 67. Morecell Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 68. Simnova Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 69. Nuwacell Revenue Growth Rate in CAR-NK Cell Therapy Business (2020-2025)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
